{"id":"W3182473146","doi":"10.1016/j.clon.2021.06.009","title":"Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma in a Population-based Cohort","year":2021,"lang":"en","type":"article","venue":"Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Victoria; University of British Columbia","funders":"Merck; AstraZeneca Canada; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Nivolumab; Discontinuation; Hazard ratio; Internal medicine; Cohort; Adverse effect; Population; Survival analysis; Proportional hazards model; Confidence interval; Oncology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005345267,0.0002135648,0.0004214791,0.000466771,0.0004045989,0.00086129,0.0003592426,0.0005985013,0.00139975],"category_scores_gemma":[0.002121385,0.0002557844,0.001093863,0.0006573056,0.0002996161,0.0007410143,0.0005617359,0.001131727,0.0001998269],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005636243,"about_ca_system_score_gemma":0.0004813447,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005177433,"about_ca_topic_score_gemma":0.005510217,"domain_scores_codex":[0.9994986,0.00007868335,0.0000378054,0.0001806502,0.00005466452,0.0001496112],"domain_scores_gemma":[0.9990028,0.0001825221,0.0004505028,0.00009321083,0.00007708408,0.0001939362],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001151053,0.00006310878,0.9956511,0.00001095232,0.0002715366,0.0001866416,0.00007321843,0.00009873018,0.0002702792,0.00002981417,0.000252175,0.001941368],"study_design_scores_gemma":[0.00004663868,0.0003189255,0.9980645,0.000007336731,0.0001844714,0.0004134264,0.0002356288,0.0002995151,0.00004282493,0.0000683778,0.0003095486,0.000008854387],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9989867,0.0002736431,0.00003344794,0.00006671911,0.000009185614,0.000003817368,0.0003415528,0.000002886286,0.0002821719],"genre_scores_gemma":[0.9993299,0.00009269096,0.0000119887,0.00003773725,0.00001592288,0.000004739171,0.0003736201,0.000001345814,0.0001320263],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005177433,"threshold_uncertainty_score":0.01029462,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05244218482308755,"score_gpt":0.4277913085962518,"score_spread":0.3753491237731643,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}